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ABSTRACT 1 
 2 
Background & Aims: Glucose is absorbed into intestine cells via the sodium glucose 3 
transporter 1 (SGLT-1) and glucose transporter 2 (GLUT2); various peptides and hormones 4 
control this process. Apelin is a peptide that regulates glucose homeostasis and is produced by 5 
proximal digestive cells; we studied whether glucose modulates apelin secretion by 6 
enterocytes and the effects of apelin on intestinal glucose absorption.  7 
 8 
Methods: We characterized glucose-related luminal apelin secretion in vivo and ex vivo by 9 
mass spectroscopy and immunological techniques. Effects of apelin on 
14
C-labeled glucose 10 
transport were determined in jejunal loops and in mice following apelin gavage. We 11 
determined levels of GLUT2 and SGLT-1 proteins and phosphorylation of AMPKα2 by 12 
immunoblotting. The net effect of apelin on intestinal glucose transepithelial transport was 13 
determined in mice.  14 
 15 
Results: Glucose stimulated luminal secretion of pyroglutaminated apelin-13 isoform (Pyr-16 
1-apelin-13) in mice small intestine. Apelin increased specific glucose flux through the 17 
gastro-epithelial barrier in jejunal loops and in vivo following an oral glucose administration. 18 
Conversely, pharmacological apelin blockade in the intestine reduced the increased glycemia 19 
that occurs following oral glucose administration.Apelin activity was associated with 20 
phosphorylation of AMPKα2 and rapid increase of GLUT2:SGLT-1 protein ratio in the 21 
brush-border membrane. 22 
 23 
Conclusion: Glucose amplifies its own transport from the intestine lumen to the bloodstream 24 
by increasing luminal apelin secretion. In the lumen, active apelin regulates carbohydrate flux 25 
 4 
through enterocytes by promoting AMPKα2 phosphorylation and modifying the ratio of 1 
SGLT-1:GLUT2. The glucose–apelin cycle might be pharmacologically handled to regulate 2 
glucose absorption and assess a better control of glucose homeostasis. 3 
 4 
Keywords: Calorie intake; mouse model; diabetes; adipokine, apelin 5 
 6 
7 
 5 
INTRODUCTION 1 
 2 
Apelin is the endogenous ligand for G protein-coupled receptor APJ
1, 2
 acting under several 3 
molecular forms (Pyr-1-apelin-13, apelin-13, -17 and -36) processed from a 77-amino acids 4 
precursor
3
.The active forms of apelin are present in peripheral tissues including lungs, heart, 5 
adipose and pancreas (for reviews see
4, 5
). In the gastrointestinaltract, mRNA apelin-6 
expressing cells were found in rat and mouse stomach, in mouse duodenum, and in human 7 
and mouse colon
1,6
. APJ immunostaining has also been described in the epithelium, goblet 8 
cells and crypt cell of the small intestine, and in the smooth muscle layer of rat 9 
gastrointestinal tract
7
. APJ is also located in the enteric blood vessels
7
. Thus, the apelin/APJ 10 
system may have a potential role in the digestive tract. 11 
 Recent studies established that apelin is involved in glucose homeostasis
8
. We 12 
demonstrated that iv injection of physiological doses of apelin decreased glycemia and 13 
stimulated glucose uptake in skeletal muscles of lean and obese insulin-resistant mice
9
. 14 
Moreover, apelin-stimulated glucose transport in muscle was dependent of AMPK activation. 15 
Similar results were described in cultured C2C12 myotubes by Yue et al.
10
. These authorsalso 16 
showed that apelin-deficient mice exhibitdecreased insulin sensitivity
10
. Taken together, such 17 
studies support the assumption that apelin plays a physiological role in glucose metabolism 18 
and maintenance of insulin sensitivity
8
. 19 
 We demonstrated that leptin and resistin-, two adipokines secreted in the 20 
gastrointestinal lumen by gastric and intestinal endocrine cells, regulate the activity of the 21 
sugar transporters in enterocytes by an AMPK-dependent mechanism
11-13
. The net effect of 22 
this regulation ofhexose transporters was an increase of sugar uptake with significant 23 
consequences on splanchnic metabolism. Interestingly, the adipokine apelin shares several 24 
features with these peptides such as i) the ability of being produced in gastrointestinaltract, ii) 25 
an implication in glucose metabolism and iii) the control of insulin sensitivity via AMPK 
10, 
26 
 6 
11
.Recent studies brought evidence of a putative regulation of apelin by glucose in different 1 
tissues. Indeed, increased amounts of apelin in response to different glucose levels
14, 15, 27 
 2 
were demonstrated in human endothelial as well as in pancreatic -cell. 3 
 This study was designed to characterize the relationship between apelin and glucose in 4 
intestine.We showthat D-glucose promotes specifically Pyr-1-apelin-13 secretion in 5 
intestine.We further demonstratein vitro and in vivothe capacity of apelin to increase glucose 6 
flux from lumen toward the bloodstream by interacting with the APJ receptor present in 7 
enterocytes. This effect appears to involve an AMPK-dependant control of SGLT-1 and 8 
GLUT2 expression in apical enterocytes membrane by apelin. Moreover, pharmacological 9 
inhibition of endogenousapelin action bya selective APJ antagonist resulted in a decrease of 10 
glycemia,supporting the existence of a glucose/apelin cyclethat regulates intestinal 11 
carbohydrates absorption.  12 
13 
 7 
METHODS 1 
 2 
AnimalsMale C57BL/6J mice (Centre Elevage Janvier, Le Genest-St-Isle, France) had free 3 
access to water and standard food. They were treated in accordance with European 4 
Community guidelines concerning care and use of laboratory animals.  5 
 6 
NanoLC-MS/MS analysis.The gastric contents were filtrated with a 10kDa membrane and 7 
injected on a NanoRS 3500 chromatographic system (Dionex, Amsterdam, The Netherlands) 8 
coupled to an LTQ-Orbitrap XL mass spectrometer (Thermo Fisher Scientific, Bremen, 9 
Germany). Five µL of each sample were separated on a 75 μm ID x 15 cm C18 column 10 
(Proxeon Biosystems, Odense, Denmark). Peptides were eluted using a 5 to 50% linear 11 
gradient of solvent B in 105 min (solvent A was 0.2% formic acid and solvent B was 0.2% 12 
formic acid in 80% ACN). Full MS scans were acquired in the Orbitrap on the 300-2000 m/z 13 
range with the resolution set to a value of 60000. An inclusion list corresponding to several 14 
charge states (2+, 3+, 4+) of [Pyr-1]-apelin-13 was used to select these ions for CID 15 
fragmentation and the resulting fragment ions were analyzed in the linear ion trap (LTQ). 16 
Dynamic exclusion was employed within 60 s to prevent repetitive selection of the same 17 
peptide. 18 
 19 
Fluorescence immunohistochemical studies and confocal microscopy 20 
Immunohistochemical staining was performed as previously described
16
 using anti-APJ 21 
polyclonal antibody (Novus Biologicals, 1/100), anti-apelin polyclonal antiserum (Covalab, 22 
1/200) and anti-GLUT2 antibody (Abcam 54460, 1/100). Nuclei were stained with TOPRO-23 
III (Invitrogen, 1/1000). Fluorescence analysis was performed utilizing a LSM510 Confocal 24 
Laser Scanning microscope. Samples were visualized with a 25X objective lens (Plan-25 
Apochromat, N.A. 1,4, Oil) and excited using three laser lines (488, 543 and 633 nm). For 26 
 8 
APJ and GLUT2 detection, control was achieved using an IgG mouse serum at the same 1 
concentration as the antibody. The specificity of apelin immunostaining was tested using 2 
primary antisera pre-absorbed with excess amount of homologous antigen ([Pyr1]-Apelin-13, 3 
10
-6
 mol/L). Densitometric quantifications of fluorescence intensity were assessed by Image J 4 
software. The results represent the apelin-integrated density – (total area x mean fluorescence 5 
of background) of 3 different pictures per mouse and 4 mice per group. 6 
 7 
Tissue preparation and short-circuit measurement Mice were 16 h fasted and euthanized. 8 
The proximal jejunum was dissected out and adjacent samples mounted in Ussing chambers. 9 
The tissues were bathed with Krebs Ringer solution (KRB) with 10 mmol/L glucose at 37°C 10 
(pH 7.4) and were gassed with 95% O2/5% CO2. Electrogenic ion transport was monitored as 11 
previously described 
11
. KRB alone (vehicle) or containing apelin (10
-10
 to 10
-6
 mol/L) was 12 
added in the mucosal bath 2 min before the 10 mmol/L-glucose challenge. Similar tests were 13 
performed with 100 nmol/L apelin incubated overnight at 4°C with 1/100 rabbit polyclonal 14 
antibody raised against apelin (Covalab, France). 15 
 16 
Transmural hexoses transport The experiments were performed using jejunal sacs from 17 
fasted mice. The proximal jejunum was dissected out and rinsed in cold saline solution. 18 
Jejunal sacs (4 cm long) were prepared for D-[1-
14
C] glucose (49.5 mCi/mmol) transport as 19 
previously described
11
. The corresponding jejunal sacs were filled with 1 ml of KRB solution 20 
without (control) or with 1 nmol/L apelin and containing 0.02 μCi/ml of the isotopic tracer D-21 
[1-
14
C] glucose (49.5 mCi/mmol) and glucose to obtain a final concentration of 30 mmol/L. 22 
Similarly, we studied the paracellular transport with 30 mmol/L mannitol and the isotopic 23 
tracer D-[1-
14C] mannitol (59 mCi/mmol) at 0.2 μCi/ml.  24 
 25 
 9 
SGLT-1, GLUT2, AMPKand APJ western blot Fastedanimals were anesthetized and 1 
laparotomized for in situ experiments. Three jejunal segments (5 cm long) were tied and filled 2 
with 3 ml of KRB without (control) or with 1 nmol/L apelin. After 3 min of in situ incubation, 3 
3 ml of 60 mmol/L glucose solution were injected in the lumen to obtain a final concentration 4 
of 30 mmol/L. After a further 5 min, these sacs were removed and opened along the 5 
mesenteric border and the mucosa was scraped off on ice with a glass blade.  6 
For APJ determination, mice were gavaged with water (control) or Pyr-1-apelin-13(200 7 
pmol/kg in 100 µl). After 10 minutes, mice were euthanatized and whole intestine was 8 
dissected on ice. The total cell protein extracts and the brush-border membranes (BBM) were 9 
prepared from the scrapings as previously described
17
.Solubilized proteins were resolved by 10 
electrophoresis on 10% SDS-PAGE gels and proceeded for immunoblotting. The 11 
followingantibodies were used at a 1:1000 dilution: SGLT-1 (AB 1352; Chemicon 12 
International); GLUT2, phospho-AMPK-α1/2 (Thr172) and AMPKα 1/2 (sc-9117, sc-33524, 13 
sc-25792, respectively; Santa Cruz Biotechnology) and 1:500 for APJ (NLS 64, Novus 14 
Biologicals). The intensity of the specific immunoreactive bands was quantified using NIH 15 
Image (Scion).  16 
 17 
In vivo luminal apelin secretion Fasted C57BL/6J mice were orally loaded by 100 l of D-18 
glucose solution (0.5 or 1 g/ml) or water (control). After 10 minutes, mice were 19 
euthanatized, whole intestine was dissected and the luminal content gently collected and 20 
immediately frozen. 21 
 22 
Apelin secretion and immunoblotting from everted intestinal sacsWhole proximal 23 
intestine was harvested, rinsed, everted and filled with PBS. Then, 1 cm long everted-24 
 10 
intestine sacs were incubated in gassed and warmed PBS with or without glucose (5 and 30 1 
mmol/L). Fifty l of media were collected at time 5, 30 and 60 min of incubation and 2 
immediately frozen in liquid nitrogen before a column-filtration step (Amicon Ultra, 10,000 3 
MWCO, Millipore) and measure of apelin concentration. To normalize results obtained, 4 
each sac was collected for protein quantification. The same experiments were done to 5 
determinate apelin-77 content in jejunal mucosa by western blotting after 60 minutes with 6 
(30 mmol/L) or without glucose in KH buffer incubation. Solubilized proteins were resolved 7 
by electrophoresis on 10% SDS-PAGE gels. Apelin-77 (Abcam 59469) and -actin (Cell 8 
Signaling Technology 13E5) antibodies were used at a 1:500 dilution. The intensity of the 9 
specific immunoreactive bands was quantified using NIH Image (Scion).  10 
 11 
Apelin’s effect on oral glucose load Gavages of fasted mice with a D-glucose solution (3 12 
g/kg of body weight) were performed. Glucose load was preceded (10 min) by a PBS 13 
(control) or a [Pyr-1]-apelin-13 (200 pmol/kg in 100 l) gavage. Ten minutes later, mice were 14 
anesthetized and the blood was harvested from hepato-portal vein for glucose (RTU kit 15 
Roche) and apelin concentration determination. Same experiments were performed in 16 
presence or absence of APJ antagonist (1 µmol/kg in 200 µl, 10 min before glucose load).  17 
 18 
APJ-mediated β-arrestin 2 recruitment measured by BRET assay Fasted mice were 19 
gavaged with apelin (200 pmol/kg in 100 µl) or APJ antagonist (1 mol/kg in 200µl) and the 20 
luminal content of proximal intestine was collected 10 minutes later and immediately frozen 21 
in liquid nitrogen. After a step of filtration and purification, apelin and antagonist’s activities 22 
of luminal content of PBS-, apelin- or APJ antagonist-gavaged mice were assessed on -23 
arrestin 2 recruitment to APJ by BRET. HEK-293T cells were transfected with the human 24 
 11 
apelin receptor tagged on its C-terminus with the BRET donor Renilla luciferase and β-1 
arrestin2 double tagged with the yellow fluorescent protein (YFP) at the N- and C-terminus. 2 
BRET approach was assayed as previously described
18
. Intrinsic activities of filtered luminal 3 
contents were measured by adding samples 5 min after the Rluc substrate coelenterazine. To 4 
determine ifthe antagonist was still active after gavage, luminal content was added 1 min after 5 
the luciferase substrate and exogenous [Pyr1]-apelin-13 was added 5 min before reading.  6 
 7 
Apelin assay Apelin was quantified with the non-selective apelin-12 EIA kit (Phoenix 8 
Pharmaceuticals, Belmont, CA). Before dosage, luminal content, plasma and conditioned 9 
medium were filtrated and concentrated by column (Amicon Ultra, 10,000MWCO, 10 
Millipore). 11 
 12 
qPCR experiments Jejunal loops were incubated during 24h in warmed oxygenated KRB 13 
containing [Pyr1]-apelin-13  (10
-6
 mol/L) or APJ-antagonist (5.10
-6
 mol/L) and/or D-glucose 14 
(30 mmol/L). After treatment, loops were rinsed in KR buffer and immediately liquid 15 
nitrogen-frozen for GLUT2 and SGLT-1 mRNA quantification as previously described.
8
. 16 
 17 
Chemicals [Pyr1]-Apelin-13 was purchased from Bachem (Switzerland), D-[1-
14
C] 18 
mannitol was from GE Healthcare Amersham Biosciences, (les Ulis, France) and D-[1-
14
C] 19 
glucose from Perkin Elmer, (Boston USA). All other chemical reagents were purchased 20 
from Sigma (St. Louis, MO). Apelin antagonist (C-14-C dicyclic19) was purchased from 21 
Polypeptide (Strasbourg, France). 22 
 23 
 12 
Statistical analysis All results were expressed as means ± SEM. One-way ANOVA with 1 
Turkey-Kramer multiple comparisons posthoc-test was performed using GraphPad Prism 2 
(GraphPad Software, San Diego, CA). Significance was set at p<0.05. 3 
4 
 13 
RESULTS 1 
Glucose increases luminal secretion of apelin in vitro and in vivoWhen administrated by 2 
gavage to mouse, exogenous glucose promotes apelin luminal secretion. Indeed, 10 minutes 3 
after an oral load with high glucose solutions (50 or 100mg in 100 l of water), luminal apelin 4 
amount measured in the collected luminal material raised by twofold (Fig. 1a). This 5 
regulation is glucose-specific and independent of osmolarity since the same concentration of 6 
mannitol did not induce apelin secretion (supplemental Fig.S1). Consequently, as shown in 7 
figure 1b and c, apelin contained in jejunal cell cytoplasm (red)was partially depleted when 8 
glucose was orally-given, leading to a significant decrease of immunoreactivity. No staining 9 
was observed when the same experiments were performed with preabsorbed immune serum 10 
(Fig. 1b, bottom panel).Taken together, these results suggest that apelin stored in the 11 
epithelial cells (supplemental fig. S2) has been released in the lumenin response to glucose. 12 
To confirm this hypothesis, we further quantified apelin secretion ex vivo on everted intestine 13 
loops from mouse duodenum and jejunum (Fig. 1e and f). Both tissues exhibit the same 14 
kinetic apelin secretion profile characterized by a dramatic increase of apelin concentration in 15 
the medium 30 minutes after incubation of everted loops with 5 or 30 mmol/L glucose 16 
solutions. After 60 minutes, similar increase was observed suggesting that maximal release of 17 
apelin was reached alreadyafter 30 minutes.Moreover, western blottings showing intracellular 18 
form of apelin (dimer of apelin-77; 16kDa) in jejunal-everted loop incubated 60 minutes with 19 
30 mmol/L of glucose corroborate these results and reinforce a glucose-dependent apelin 20 
release (Fig. 1d).Then, in order to determine ifimmunoreactive quantification of apelin was 21 
specific of one isoform, we performed mass-spectrometry(MS) analysisof gastric secretions 22 
collected from PBS-, apelin- or glucose-gavaged mice. AsPyr-1-apelin-13(resulting from a 23 
pyroglutamination of apelin-13) is the most stable isoform in aqueous phases, 24 
comparisonswere done witha control profile processed with synthetic Pyr-1-apelin-13 alone 25 
 14 
(data not shown and 
20
) or addedin PBS-treated mice luminal content(figure 2a). Figure 1 
2ashows that after purification and filtration steps of gastric secretions, spiked synthetic Pyr-2 
1-apelin-13 can be recovered by this technique. Figures 2b and 2e (middle panel) show that 3 
after Pyr-1-apelin-13 gavage, the same peptide is recovered in intestinal lumen of mice after 4 
10 minin contrast to PBSorally-load mice(figure 2d). Moreover, after glucose load (1g/ml), 5 
Pyr-1-apelin-13was also detected in gastric secretions (figure 2c and 2e; lower panel) in the 6 
same extend. FurtherMS experiments and analysis based on ion signal extraction indicated 7 
that other apelin isoforms were not recovered in glucose-load mice lumen secretions when 8 
compared to their published MS profile (supplemental figure S3). 9 
 10 
Exogenous apelin binds APJ receptor present in brush-border membrane of 11 
enterocyteand controls abundance of glucose transporters in BBM.As apelin secretion 12 
appears to be controlled by glucose, we investigated the reciprocal role of Pyr-1-apelin-13 13 
on enterocyte glucose pathways. We first measured the presence of apelin receptor on small 14 
intestine. Fluorescent immunohistological studies were performed on mouse jejunal mucosa 15 
sections showing that apelin receptor (APJ) is expressed in villi associated primarily with the 16 
cell membrane (Fig. 3a). No staining was observed when the same experiments were 17 
performed with non-specific IgG antibody. Moreover, immunoreactive signal corresponding 18 
to apelin receptor APJ was found by western blotting in total proteins (fig 3b) and brush-19 
border membranes (fig 3c) from mice enterocytes. Significant signal was found in BBM in 20 
basal condition indicating a constitutive expression of APJ receptor. However, 21 
immunoreactive signal was 3.9-fold decreased (p=0.013) when [Pyr-1]-apelin-13 was given to 22 
the mice (Fig.3c) suggesting effective activation of APJ receptor by exogenous Pyr-1-23 
apelin-13 and consequently APJ internalization. 24 
 15 
Intestinal glucose physiology is characterized by post-translational regulationofglucose 1 
transporter abundance in BBM. We thus examined ex vivo whether apelin modifies glucose 2 
transporters amount and activityon jejunal loops. As expected, glucose (10 mmol/l) induced a 3 
2.4-fold increase of SGLT-1 amounts in BBM compared to controls (Fig.4a). Apelin (1 4 
nmol/l) alone significantly reduced the basal level of SGLT-1 (p<0.01) and markedly 5 
prevented glucose-increase in SGLT-1 abundance (p<0.001) when injected into the loop 3 6 
minutes before glucose (Fig. 4a).  7 
The effect of apelin on SGLT-1 activity was then studied using Ussing chamberon mice 8 
jejunum isolated. As previously described
11, 12, 21
, the addition of 10 mmol/L D-glucose to the 9 
mucosal bath of Ussing chamber induced a rapid and marked increase in Isc (vs. basal 10 
conditions), reaching a plateau after 3-4 minutes. Addition of apelin in mucosal compartment 11 
3 minutes before glucose challenge markedly reduced the glucose-induced Isc (ΔIsc). As 12 
depicted in figure 4b, the inhibition of ΔIsc was dose-dependentwith a maximal inhibition of 13 
0.1 µmol/L and an IC50 of 0.1 nmol/L. Overnight incubation with apelin antibody totally 14 
blocked the inhibitory effect of the peptide (Fig. 4c). Since SGLT-1 expression is balanced 15 
byGLUT2 expression 
14
, the effect of apelin on GLUT2 was studied. Apelin induces a 16 
significant increase in the abundance of GLUT2 in BBM (p<0.05) (Fig. 4d). Glucose alone 17 
induces a 2.1-fold increase in apical GLUT2 protein andapelin co-incubated with glucose 18 
resulted in a significant increase in immunoreactive GLUT2 over the value of glucose or 19 
apelin alone indicating an amplification mechanism or additive effects via distinct pathways 20 
(Fig. 4d).  21 
Since AMPK is a key-regulator of glucose transporter in enterocyte, we measured the effect 22 
of apelin on the phosphorylation of AMPKα2 subunit. Apelin alone significantly stimulated 23 
AMPKα2 phosphorylation (Fig. 4e). This effect was less marked when compared with 24 
glucose alone but when apelin was injected in the jejunal loop together with glucose, the 25 
 16 
phosphorylation of AMPKα2 was significantly enhanced showing an additive effect of apelin 1 
and glucose (Fig. 4e). 2 
 3 
Apelin stimulates transepithelial transport of 
14
C-glucosethrough GLUT2 4 
regulationSince AMPKα2 activation is associated with glucose flux control in enterocyte13, 5 
we investigated[Pyr-1]-apelin-13 effect on transmural hexoses transport (Fig. 5). As shown in 6 
Fig. 5a, Pyr-1-apelin-13 (1 nmol/L) significantly increased 30 mmol/L glucose uptake in the 7 
isolated mice jejunum. This effect was fast (2 min after apelin addition) and glucose specific. 8 
Indeed, no effect on 10 mmol/L mannitol uptakewas observed indicating that the increased 9 
transport of glucose induced by apelin was unlikely to be caused by changes in paracellular 10 
permeability (Fig. 5b). To better understand the apelin’s pathways allowing this glucose flux, 11 
we performed the same experiment in presence of phloretin, a GLUT transporter selective 12 
inhibitor. The results show that the transepithelial glucose transport stimulated by apelin is 13 
significantly decreased to control value in presence of the inhibitor suggesting that GLUT2 14 
translocation is necessary for apelin’s effect (Fig. 5c). 15 
 16 
Orally-given apelinincreases intestinal transepithelial glucosetransport from lumen to 17 
bloodstreamin mice 18 
The net effect of oral apelin on glucose absorption was further investigated. For that purpose, 19 
the consequence of an oral administration of Pyr-1-apelin-13 on hepato-portal glucose 20 
concentration was studied duringan oral glucose load in fasted mice. Orally-given apelin 21 
dramatically increasedglucose concentration in hepato-portal vein15 minutes after glucose 22 
load (Fig. 6a). Then, in order to demonstrate thephysiological effect of endogenous apelin 23 
production on intestine glucose uptake,we inhibited theglucose/apelin cycle by using a 24 
specific APJ antagonist
19
orally-given 10 minutes before the glucose load.Data presented in 25 
 17 
figure 6b show that 1 mol/kg antagonist promoted a marked reduction of plasmatic glucose 1 
10 and 20 minutes after the glucose load. This result clearly indicates that 2 
apelinphysiologically promotes carbohydrates absorption.Finally, to evaluate the long-term 3 
effect of both apelin and APJ-antagonist, we studied the consequence of a 24h-treatment on 4 
SGLT-1 and GLUT2 mRNA level (Fig. 6c). As expected, GLUT2 was significantly increased 5 
while SGLT-1 mRNA level was decreased by 30 mmol/l glucose. Apelin had the same effect 6 
than glucose on carbohydrate transporters mRNA expression.Such effects were blunted by 7 
APJ-antagonist treatment.  8 
 9 
Exogenous apelin given by gavage remains active in the proximal intestine  10 
To know if exogenous Pyr-1-apelin-13 and APJ-antagonist orally-given to mice are still 11 
active when they reach proximal intestine, the luminal content was collected 15 minutes after 12 
gavage, purified, filtered and tested for APJ-inducing -arrestin 2 recruitment. Control of cell 13 
transfection as well as BRET experiment validity obtained by increasing doses of apelin are 14 
presented in supplemental data (supplemental figure S5). Luminal content collected from 15 
Pyr-1-apelin-13 orally-loaded mice displayed a significant rise in BRET signal compared to 16 
PBS-stuffed mice, indicating that orally-loaded apelin is active and induces arrestin 17 
recruitment to the membrane (Fig. 7a). Conversely, when APJ-antagonist was given by 18 
gavage to mice, the resulting luminal content did not modify basal APJ activity by BRET. 19 
Finally, the efficiency of the APJ-antagonist collected after gavage was studied on apelin-20 
induced BRET signal (Fig. 7b and c). As expected, exogenous Pyr-1-apelin-13 added to 21 
cells (10
-7
 mol/L and 10
-6
 mol/L, Fig. 7b and c respectively) induced a significant increase in 22 
BRET signal. This effect was totally blunted by lumen content from APJ-antagonist orally-23 
loaded mice when 10
-7
 mol/L exogenous apelin was used (Fig. 7b.) but not for a higher dose 24 
of the peptide (10
-6
 mol/L, Fig. 7c). These results demonstrate that exogenous Pyr-1-apelin-25 
 18 
13and APJ-antagonist remain efficient when they reach glucose absorption zones of the 1 
intestine, i.e. duodenum and jejunum. 2 
3 
 19 
DISCUSSION 1 
 This study demonstrates the presence of a regulatory intestinal loop between apelin 2 
and glucose leading to a rapid regulation of intestinal glucose absorption. In order to 3 
insurebalanced glucose absorption during or after a meal, the activity of sugar transporters in 4 
the enterocytes appears highly regulated. Indeed, glucose itself is able to promote its own 5 
transit through the intestinal barrier towards bloodstream by a fine regulation of SGLT-1 and 6 
GLUT2 abundance in the BBM
22
. Recent studies describedotheractors of glucose absorption 7 
implicating hormones such as CCK
23
, angiotensin II
24
, insulin
25
, leptin
11
, RELM-β12 or 8 
GLP1/2
26
. Apelinshares characteristics features with these hormones, particularly with leptin, 9 
since both are increased with obesity, target the intracellular AMPK and are closely related to 10 
glucose homeostasis and insulin sensitivity through their action on skeletal muscle and 11 
adipose tissue
9, 27
. In this study, we demonstrate by different approaches that glucose 12 
specifically enhances Pyr-1-apelin-13 secretion from intestine cells into the lumenwithout 13 
modifications in plasma apelin (supplemental fig. S4). This is in line with our previous 14 
demonstration that luminal secretion of gut leptin was observed without any modification of 15 
blood leptin levels in rat 
13
.Eventhough apelin and glucose have been tightly associated in 16 
several studies, the direct effect of glucose on a putative apelin secretion has been poorly 17 
described. Yamagata et al. have recently shown that human endothelial cultured cells secrete 18 
apelin in response to glucose andRingstrom et al. describeda slight increase of mRNA apelin 19 
in isolated human pancreatic islets after glucose stimulation
15, 28
. In our study, although 20 
concentrations of glucose used ex vivo(30 mmol/L) are physiologically relevant and 21 
comparable to other studies
12, 13
, in vivoexperiments required higher doses of glucose (up to 22 
100mg/100l) to ensure that a significant amount of glucose reaches small intestine few 23 
minutes after oral load.  24 
 20 
Apelin secretion in the lumen in response to sugar is in line with previous demonstration of 1 
luminal leptin secretion in the intestine after fructose load
13
. The question arises of 2 
bioavailability of peptides in the lumen characterized by its acidic pH and proteolytic 3 
enzymes activity. Interestingly, orally-given apelin remains active as shown by APJ activation 4 
and BRET studies. Leptin was shown to besecreted in the lumen together with a soluble 5 
receptor allowinga protection from degradation by proteolytic enzymes
29
.It could be 6 
hypothesized that such an associated protein could exist for apelin and further consideration 7 
to propose pharmacological modulations of luminal free/bound apelin concentrations are 8 
needed.  9 
This glucose-induced luminal apelin secretion led us to investigate the functional 10 
effect of Pyr-1-apelin-13 on glucose absorption. We showed by different approaches that 11 
physiological concentration of apelinenhances glucose transmural transport from lumen to the 12 
bloodstream.This effect is specific for glucose and not associated with modifications of 13 
enterocytes tight-junction’s permeability since mannitol is not translocated from the lumen to 14 
the serosal side in presence of apelin. Our results also show that, consistently with previous 15 
works in muscle and adipose tissue
9, 30
, apelin can also activate AMPK in enterocytes. AMPK 16 
is an important glucose sensor in enterocyte
13, 31
and its activation mustinitiate apelin’s effects 17 
on glucose transportersbalance. Indeed, apelin induces ex vivodecrease of SGLT-1 in BBM 18 
whereas GLUT2 expression wasincreased. SGLT-1 is a high-affinity low-capacity glucose 19 
carrier constitutively expressed in the BBM of epithelial cell lining the small intestine lumen. 20 
SGLT-1 is responsible for luminal glucose uptake against concentration gradient using a 21 
membrane potential generated by the sodium pump
32
. Conversely, when glucose 22 
concentration increases in the small intestine lumen, mechanisms including PKA, PKCβII and 23 
AMPKα2 activation are rapidly activated to traffic GLUT2 into the BBM.The fact that Pyr-24 
1-apelin-13 controls SGLT-1’s activity and further triggers a switch in glucose transporters 25 
 21 
SGLT-1/GLUT2 ratio, activities and gene expression, givesa new insight into control of 1 
physiological sugar absorption by apelin.It has been reported
16
 that GLUT2 is over-expressed 2 
in enterocytes during metabolic diseases which could participate to post-absorptive elevated 3 
glycemia. Thus, as showed here, pharmacological approach consisting in the blockade of 4 
theglucose/apelin cycle by using oral APJ antagonistcould beused to lower glucose 5 
absorption. 6 
 In summary, the present data show the involvement of the apelinergic system in 7 
mechanisms controlling the intestinal absorption of glucose. As we recently described a 8 
putative role for apelin in glucose uptake in muscle and adipose tissue, it could be 9 
hypothesized that apelin firstly acts by enhancing intestinal glucose uptake from digested 10 
sugars in order to secondarily furnish energetic substrate to apelin-activated tissues. 11 
Consequently, intestinal apelin regulation by pharmacological agents such as APJ 12 
antagonistscould allow a better controlof blood sugaramounts after a meal. This process could 13 
be compared to the effect of lipase inhibitorsthat areclinically used to avoid lipid 14 
absorption.Finally, the present study brings new paradigm on luminal secretion, 15 
bioavailability and efficiency of gut peptides and paves the way for future utilization of apelin 16 
or apelin-antagonist by oral route.  17 
 18 
19 
 22 
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LEGENDS TO FIGURES 1 
Figure 1: D-glucose triggers intestinal apelin secretion. a)In vivo apelin secretion 2 
measured in luminal fluid collected from proximal part of intestine after gavage. n=5; * 3 
p<0.05 vs. no glucose. b)and c)Confocal micrographs (x25 top line and x50 middle line) of 4 
jejunum sections from mice treated or not with oral glucose load (50 and 100 mg in 100 l) 5 
and stained with anti-apelin immune serum. Immune serum preincubated with an excess of 6 
apelin was used as control (bottom line). The white bars represent 100 m. c) Densitometric 7 
quantification of apelin immunoreactivity in jejunum. n=4; * p<0.05, **p<0.01 vs. no 8 
glucose. d) Representative immunoblots of intracellular apelin-77 from mice jejunum sacs 9 
treated with 30 mmol/L glucose. Data of densitometric analysis are expressed as relative 10 
protein levels (β-actin as control) n=3; * p<0.01.e) and f) Kinetics of apelin secretion by 11 
duodenum or jejunum evertedsacs in medium without (0) or withglucose (5 or 30 mmol/L). 12 
n=5; * p<0.05.  13 
 14 
Figure 2: D-glucose induces in vivo Pyr-1-apelin-13 isoform luminal secretion. 15 
Extracted ion chromatograms of the pQRPRLSHKGPMPF sequence of Pyr-1-apelin-13 in 16 
gastric secretions of mice gavaged with PBS plus 2 picomoles of synthetic Pyr-1-apelin-13 17 
added before MS analysis (a) synthetic Pyr-1-apelin-13(b), glucose(c) and in gastric 18 
secretion of mice treated with PBS (d). e) Manually annotated MS/MS fragmentation spectra 19 
of the pQRPRLSHKGPMPF peptide obtained from experiments a (upper panel), b (middle 20 
panel) and c (lower panel). f) Sequence of Pyr-1-apelin-13. 21 
 22 
Figure 3: Presence of APJ in enterocytes and activation by apelina) Jejunum sections 23 
from mice stained with anti-APJ antibody, Topro III or both. Pictures are representative of 4 24 
mice. Control was achieved with non-specific IgG antibodies. Photomicrographs are 50x 25 
 24 
magnification, the white bar represents 100 m. b) and c) Representative immunoblots of APJ 1 
and β-actin in jejunum from mice orally-loaded by  pyr1-apelin-13 (200pmol/kg) (A1, A2, 2 
A3) or PBS (C1, C2, C3). Protein detection was achieved from whole jejunum (b) or from 3 
BBM purified material (c). Data of densitometric analysis using β-actin as control. * p<0.05 4 
 5 
Figure 4: Luminal apelin promotes AMPK phosphorylation and controls SGLT-1 and 6 
GLUT2 presence in enterocyte BBM a) Representative immunoblots of SGLT-1 from mice 7 
jejunum sacs treated with or without pyr1-apelin-13 in association or not with 30 mmol/L 8 
glucose. Data of densitometric analysis using β-actin as control. * p <0.05 **,p<0.01 and *** 9 
p<0.001 vs. NaCl. b)Effect of luminal pyr1-apelin-13on glucose-induced Isc. Electrogenic 10 
sodium transport was followed in mouse jejunum in Ussing chamber as an index of active 11 
glucose transport by SGLT-1.pyr1-apelin-13was added in bath 2 min before10 mmol/l 12 
glucose.c)Effect of 10 nmol/l pyr1-apelin-13 on glucose-induced Isc.after an overnight 13 
incubation with an antibody against apelin (Apelin+Ab.) n = 5-7 tissues studied. * p<0.05.d) 14 
Representative immunoblots of GLUT2 proteins in extracts from jejunum mucosa treated 15 
with luminal apelin with or without 30 mmol/L glucose. Densitometric analysis of the blots 16 
using β-actin as control. * p<0.05, ** p<0.01 and *** p<0.001 vs. NaCl. e) Effect of apelin on 17 
phosphorylation of AMPKα2 in the jejunum.  Phosphorylated AMPKα to total AMPK was 18 
used for densitometric analysis. * p<0.05 and ** p<0.01 vs. NaCl. 19 
 20 
Figure 5 Apelin increases transmural transport of D-glucose in jejunal sacthrough 21 
GLUT2 control a) Kinetic of transmural transport of glucose was performed in jejunal sacs 22 
from mice. Intestinal sacs were incubated during 15 min with 1 nmol/L apelin () or vehicle 23 
(□) in KRB containing glucose (30 mmol/L) and D-[1-14C] glucose. Data are representative of 24 
four experiments, * p < 0.05 vs. control. b) Similar experiment with 30 mmol/L mannitol. * p 25 
 25 
< 0.05 vs. control. c) Effect of GLUT2 inhibitor phloretin (1 mmol/L) on apelin-induced 1 
glucose transportin jejunal sacs from four mice. * p < 0.05 vs. NaCl. 2 
 3 
Figure 6:In vivo effect ofPyr-1-apelin-13 on intestinal glucose absorptiona)Apelin (200 4 
pmol/kg in 100 l (black bar) or PBS (100 l, white bar) was administrated to mice by gavage 5 
10 min before oral glucose load (3 g/kg). Ten minutes after the glucose load, blood was 6 
collected from hepato-portal vein for glucose determination. Data are given as mean ± SEM 7 
(n=8) per group. ** p<0.01 vs. PBS.b)Glycemia after oral glucose load (3g/kg) performed 8 
without (white) or with (black) APJ antagonist (1 µmol/kg body weight, 200 l) given orally 9 
10 minutes before glucose load. ** p < 0.01 vs. PBS. c) GLUT2 and SGLT-1 mRNA 10 
expression in everted jejunal loops treated by pyr1-apelin-13 (10-6 mol/L), APJ-antagonist 11 
(5.10
-6
mol/L) and/or glucose (30 mmol/L) during 24h. Results are the mean ± SEM of 5 mice. 12 
* p <0.05 vs. Ct; ** p <0.01 vs. Ct; # p <0.05 vs. glucose. 13 
 14 
Figure 7:Orally-given Pyr-1-apelin-13 and APJ-antagonist activityon APJ 15 
internalization a) Effect of luminal contents on net BRET signal in transfected cell. Content 16 
of proximal intestine was collected 10 min after PBS, apelin or APJ-antagonist mouse gavage 17 
and filtered and purified by column (see Methods). n=4-5 mice per group. ** p <0.01 vs. 18 
PBS. b) and c) Effect of luminal content collected from mice staffed with PBS or APJ-19 
antagonist on exogenous synthetic pyr1-apelin-13 (10-7 mol/L and 10-6 mol/L respectively)- 20 
mediating -arrestin 2 recruitment to APJ measured by BRET. n=5 mice per group. ** p 21 
<0.01 vs. pyr1-apelin-13 alone. 22 
 23 
 24 
25 
 26 
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